Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Assets (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Current Assets for 14 consecutive years, with $103.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 34.08% year-over-year to $103.1 million, compared with a TTM value of $103.1 million through Dec 2025, down 34.08%, and an annual FY2025 reading of $103.1 million, down 34.08% over the prior year.
  • Current Assets was $103.1 million for Q4 2025 at Karyopharm Therapeutics, up from $89.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $350.2 million in Q4 2022 and bottomed at $89.7 million in Q3 2025.
  • Average Current Assets over 5 years is $220.2 million, with a median of $237.8 million recorded in 2021.
  • The sharpest move saw Current Assets increased 27.05% in 2022, then plummeted 53.07% in 2025.
  • Year by year, Current Assets stood at $275.6 million in 2021, then grew by 27.05% to $350.2 million in 2022, then plummeted by 33.2% to $233.9 million in 2023, then tumbled by 33.11% to $156.5 million in 2024, then crashed by 34.08% to $103.1 million in 2025.
  • Business Quant data shows Current Assets for KPTI at $103.1 million in Q4 2025, $89.7 million in Q3 2025, and $97.9 million in Q2 2025.